Abstract

PORTELA-ORTIZ, José Manuel et al. Remimazolam: the ideal agent for sedation, induction and maintenance of anesthesia?. Rev. mex. anestesiol. [online]. 2023, vol.46, n.3, pp.204-207.  Epub Sep 08, 2023. ISSN 0484-7903.  https://doi.org/10.35366/111077.

Remimazolam is a new benzodiacepine that combines the pharmacological properties of two agents used in anesthesia: the hypnotic effect of midazolam and the metabolism of remifentanyl. Remimazolam is hydrolized by nonspecific tissue esterases into inactive metabolytes, allowing high clearance and fast recovery. Due to its pharmacological characteristics, it has been proposed as an ultra- short acting agent for sedation out operating room, induction and maintenance of anesthesia, as well as for sedation in the Intensive Care Unit. Remimazolam has an elevated safety profile, as it might that, it has less pronounced hemodynamic and cardiorespiratory effects in contrast to other drugs used in the same procedures. Like other benzodiacepines, remimazolam effects can be reversed with flumazenil. Remimazolam has proven to be an effective hypnotic agent, however further research and clinical evaluation is required to establish its use.

Keywords : remimazolam; pharmacological propierties; sedation in intensive care unit; anesthetic inductor.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )